Hong Kong S.a.r.
Founded in 2015, ORI Capital is a healthcare venture capital firm that invests in innovative early-stage biotech companies globally. ORI Capital leverages a proprietary quantimental strategy combining AI assisted big data with fundamental research and an experienced team of healthcare specialists to invest in the areas of diagnostics, drug delivery, and therapeutics focused on disease areas with the highest mortality rates including cancer, cardiovascular, and neurodegenerative diseases. ORI Capital’s mission is to be both financially successful for its investors and socially impactful for patients worldwide.
13
Total Investments
9
Portfolio Companies
-
Exits
3
Industries
General Information
Industries
Finance, Financial Services +1
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About ORI Capital
Recent Investments (13)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Series E | •••••• | Nov 2022 | |
| Series A | •••••• | Oct 2021 | |
| Series D | •••••• | Dec 2020 | |
| Series C | •••••• | May 2020 | |
| Series C | •••••• | Mar 2019 | |
•••• ••••
|
Series B | •••••• | Oct 2018 |
|
•••• ••••
|
Series B | •••••• | Dec 2017 |
|
•••• ••••
|
Series B | •••••• | Nov 2017 |
|
•••• ••••
|
Series B | •••••• | Nov 2017 |
|
•••• ••••
|
Series D | •••••• | Mar 2017 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.
